Literature DB >> 2545345

ABH blood group antigen expression, synthesis, and degradation in human colonic adenocarcinoma cell lines.

R Dahiya1, S H Itzkowitz, J C Byrd, Y S Kim.   

Abstract

The synthesis of blood group ABH antigens is under genetic control, where the primary gene products are glycosyltransferases. Several studies have demonstrated cancer-associated alterations in ABH antigen expression in human colon cancer tissues. However, the mechanism(s) responsible for these alterations has not been elucidated. Therefore, experiments were conducted using nine established colon cancer cell lines (four type O, three type A, and two type B) to examine ABH antigen expression by immunocytochemistry and correlate this with activities of ABH biosynthetic (glycosyltransferase) and degradative (glycosidase) enzymes. The products of the glycosyltransferase enzymes were characterized by high performance liquid chromatography and paper chromatography, and substrate affinities (apparent Km values) of the cancer cell-derived glycosyltransferases were analyzed. The present data demonstrate: (a) all cell lines except H-498 (blood type A) expressed the appropriate ABH glycosyltransferase as well as all three glycosidases; (b) product characterization and substrate dependence experiments suggested that the cancer cell-derived ABH glycosyltransferase enzymes had properties that were similar to those of the ABH enzymes in human serum; (c) H-498 cells exhibited A antigen deletion with accumulation of H precursor substance, most likely due to insufficient A transferase activity; (d) SW1417 cells (blood type B) demonstrated B antigen deletion without precursor accumulation, despite adequate levels of B transferase and low alpha-galactosidase activity; and (e) weak incompatible A antigen expression occurred in LoVo (type B) and SW1116 (type O) cells, and weak incompatible B antigen expression occurred in H-498 (type A) and SW1116 cells. However, since these cells lacked incompatible A or B transferase activity, these incompatible antigens are probably not the true A or B antigens. Thus, the colon cancer cell lines used in this study exhibit all of the ABH alterations previously described in colon cancer tissues and appear to be useful experimental models for studying the molecular events involved in cancer-associated ABH expression.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545345

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

2.  Isotopic labeling with cellular O-glycome reporter/amplification (ICORA) for comparative O-glycomics of cultured cells.

Authors:  Matthew R Kudelka; Alison V Nairn; Mohammed Y Sardar; Xiaodong Sun; Elliot L Chaikof; Tongzhong Ju; Kelley W Moremen; Richard D Cummings
Journal:  Glycobiology       Date:  2018-04-01       Impact factor: 4.313

3.  Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.

Authors:  Xingchen Shang; Xia Zhong; Xingsong Tian
Journal:  Tumour Biol       Date:  2016-03-02

4.  An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3.

Authors:  H Durbin; S Young; L M Stewart; F Wrba; A J Rowan; D Snary; W F Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

5.  A, B, H, and Lewis-a and Lewis-b blood group antigens in human breast cancer: correlation with steroid hormone receptor and disease status.

Authors:  H A Idikio; V Manickavel
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

6.  Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis.

Authors:  R S Bresalier; Y Niv; J C Byrd; Q Y Duh; N W Toribara; R W Rockwell; R Dahiya; Y S Kim
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

7.  High Diversity of Glycosphingolipid Glycans of Colorectal Cancer Cell Lines Reflects the Cellular Differentiation Phenotype.

Authors:  Di Wang; Katarina Madunić; Tao Zhang; Oleg A Mayboroda; Guinevere S M Lageveen-Kammeijer; Manfred Wuhrer
Journal:  Mol Cell Proteomics       Date:  2022-04-28       Impact factor: 7.381

8.  P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.

Authors:  R Dahiya; G Deng; K M Chen; R M Chui; P C Haughney; P Narayan
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

9.  Development and characterization of a novel anti-fucosylated antigen monoclonal antibody YB-2 and its usefulness in the immunohistochemical diagnosis of colorectal cancer.

Authors:  S Yazawa; S Akamatsu; T Tachikawa; H Naito; J Nakamura; T Asao; Y Nagamachi; T Nakajima; S Shin; D Chia
Journal:  Jpn J Cancer Res       Date:  1993-06

10.  Colorectal cancer cell lines show striking diversity of their O-glycome reflecting the cellular differentiation phenotype.

Authors:  Katarina Madunić; Tao Zhang; Oleg A Mayboroda; Stephanie Holst; Kathrin Stavenhagen; Chunsheng Jin; Niclas G Karlsson; Guinevere S M Lageveen-Kammeijer; Manfred Wuhrer
Journal:  Cell Mol Life Sci       Date:  2020-03-31       Impact factor: 9.261

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.